{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:07:08Z","timestamp":1793416028225,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02585-7","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T04:31:27Z","timestamp":1734582687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Current perspectives on vaccines and therapeutics for Lassa Fever"],"prefix":"10.1186","volume":"21","author":[{"given":"Bryce M.","family":"Warner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Safronetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2585_CR1","unstructured":"Roberts L. Nigeria hit by unprecedented Lassa fever outbreak."},{"key":"2585_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coviro.2019.07.009","volume":"37","author":"LE Garnett","year":"2019","unstructured":"Garnett LE, Strong JE. Lassa fever: with 50 years of study, hundreds of thousands of patients and an extremely high disease burden, what have we learned? Curr Opin Virol. 2019;37:123\u201331.","journal-title":"Curr Opin Virol"},{"key":"2585_CR3","doi-asserted-by":"crossref","unstructured":"McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155[3]:437\u2009\u2013\u200944.","DOI":"10.1093\/infdis\/155.3.437"},{"key":"2585_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-016-0621-4","volume":"13","author":"AE O\u2019Hearn","year":"2016","unstructured":"O\u2019Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, Fair JN, Gonzalez JP, Schoepp RJ. Serosurveillance of viral pathogens circulating in West Africa. Virol J. 2016;13:1\u20136.","journal-title":"Virol J"},{"key":"2585_CR5","unstructured":"An update of. Lassa fever outbreak in Nigeria for Week 52. Nigeria Centre for Disease Control, [December 2019]."},{"key":"2585_CR6","doi-asserted-by":"crossref","unstructured":"Adepoju P. Lassa fever in Nigeria. The Lancet Microbe. 2024 Aug 20.","DOI":"10.1016\/j.lanmic.2024.100960"},{"issue":"8","key":"2585_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/trstmh\/trv047","volume":"109","author":"AQ Mylne","year":"2015","unstructured":"Mylne AQ, Pigott DM, Longbottom J, Shearer F, Duda KA, Messina JP, Weiss DJ, Moyes CL, Golding N, Hay SI. Mapping the zoonotic niche of Lassa fever in Africa. Trans R Soc Trop Med Hyg. 2015;109(8):483\u201392.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2585_CR8","doi-asserted-by":"crossref","unstructured":"Safronetz D, Lopez JE, Sogoba N, Traore SF, Raffel SJ, Fischer ER, Ebihara H, Branco L, Garry RF, Schwan TG, Feldmann H. Detection of Lassa virus, Mali. Emerg Infect Dis. 2010;16[7]:1123.","DOI":"10.3201\/eid1607.100146"},{"key":"2585_CR9","doi-asserted-by":"crossref","unstructured":"Whitmer SL, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, Brown SM, Davis WG, Klena JD, Rollin PE, Schmidt-Chanasit J. New lineage of Lassa virus. Togo, 2016. Emerging infectious diseases. 2018;24[3]:599.","DOI":"10.3201\/eid2403.171905"},{"issue":"1","key":"2585_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcv.2007.11.019","volume":"42","author":"P Emmerich","year":"2008","unstructured":"Emmerich P, G\u00fcnther S, Schmitz H. Strain-specific antibody response to Lassa virus in the local population of West Africa. J Clin Virol. 2008;42(1):40\u20134.","journal-title":"J Clin Virol"},{"key":"2585_CR11","doi-asserted-by":"crossref","unstructured":"Grant DS, Engel EJ, Roberts Yerkes N, Kanneh L, Koninga J, Gbakie MA, Alhasan F, Kanneh FB, Kanneh IM, Kamara FK, Momoh M. Seroprevalence of anti-lassa virus IgG antibodies in three districts of Sierra Leone: a cross-sectional, population-based study. PLoS Negl Trop Dis. 2023;17[2]:e0010938.","DOI":"10.1371\/journal.pntd.0010938"},{"key":"2585_CR12","doi-asserted-by":"crossref","unstructured":"McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. Lassa fever. N Engl J Med. 1986;314[1]:20\u2009\u2013\u20096.","DOI":"10.1056\/NEJM198601023140104"},{"key":"2585_CR13","unstructured":"World Health Organization. Lassa Fever [Internet]. Switzerland: World Health Organization. 2019. https:\/\/www.who.int\/teams\/blueprint\/lassa-fever"},{"key":"2585_CR14","unstructured":"Coalition for Epidemic Preparedness Innovations. Lassa fever [Internet]. Norway: Coalition for Epidemic Preparedness Innovations. 2024. https:\/\/cepi.net\/lassa-fever"},{"key":"2585_CR15","doi-asserted-by":"crossref","unstructured":"Smith DR, Turner J, Fahr P, Attfield LA, Bessell PR, Donnelly CA, Gibb R, Jones KE, Redding DW, Asogun D, Ayodeji OO. Health and economic impacts of Lassa vaccination campaigns in West Africa. Nat Med. 2024 Aug;28:1\u20130.","DOI":"10.1101\/2024.02.26.24303394"},{"key":"2585_CR16","unstructured":"Inovio Pharmaceuticals. Safety, tolerability and immunogenicity of INO-4500 in healthy volunteers, [2020] https:\/\/clinicaltrials.gov\/study\/NCT03805984"},{"key":"2585_CR17","unstructured":"A Trial to. Evaluate the Optimal Dose of MV-LASV [V182-001], [2019] https:\/\/clinicaltrials.gov\/show\/NCT04055454"},{"key":"2585_CR18","unstructured":"A Clinical Trial to. Evaluate the Safety and Immunogenicity of rVSV\u2206G-LASV-GPC Vaccine in Adults in Good General Heath, [2021] https:\/\/clinicaltrials.gov\/study\/NCT04794218"},{"key":"2585_CR19","unstructured":"A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa, [2024]. http:\/\/clinicaltrials.gov\/study\/NCT05868733"},{"key":"2585_CR20","doi-asserted-by":"crossref","unstructured":"Matassov D, DeWald LE, Hamm S, Nowak RM, Gerardi CS, Latham TE, Xu R, Luckay A, Chen T, Tremblay M, Shearer J. Preclinical Safety Assessment of the EBS-LASV Vaccine candidate against Lassa Fever Virus. Vaccines. 2024;12[8]:858.","DOI":"10.3390\/vaccines12080858"},{"key":"2585_CR21","doi-asserted-by":"crossref","unstructured":"Sulis G, Peebles A, Basta NE. Lassa fever vaccine candidates: a scoping review of vaccine clinical trials. Tropical Med Int Health. 2023;28[6]:420\u2009\u2013\u200931.","DOI":"10.1111\/tmi.13876"},{"key":"2585_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2016.138","volume":"173","author":"JB Prescott","year":"2017","unstructured":"Prescott JB, Marzi A, Safronetz D, Robertson SJ, Feldmann H, Best SM. Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol. 2017;173:195\u2013207.","journal-title":"Nat Rev Immunol"},{"key":"2585_CR23","doi-asserted-by":"crossref","unstructured":"Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J Virol. 2009;83[11]:5890\u2009\u2013\u2009903.","DOI":"10.1128\/JVI.01948-08"},{"key":"2585_CR24","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1128\/JVI.74.5.2186-2192.2000","volume":"745","author":"J ter Meulen","year":"2000","unstructured":"ter Meulen J, Badusche M, Kuhnt K, Doetze A, Satoguina J, Marti T, Loeliger C, Koulemou K, Koivogui L, Schmitz H, Fleischer B. Characterization of human CD4\u2009+\u2009T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol. 2000;745:2186\u201392.","journal-title":"J Virol"},{"issue":"1","key":"2585_CR25","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ. Non-neutralizing antibodies elicited by recombinant lassa\u2013rabies vaccine are critical for protection against Lassa fever. Nat Commun. 2018;9(1):4223.","journal-title":"Nat Commun"},{"key":"2585_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"212","author":"RF Garry","year":"2023","unstructured":"Garry RF. Lassa fever\u2014the road ahead. Nat Rev Microbiol. 2023;212:87\u201396.","journal-title":"Nat Rev Microbiol"},{"key":"2585_CR27","doi-asserted-by":"crossref","unstructured":"Kaka\u012b CG, Okunromade OF, Dan-Nwafor CC, Chabi AI, Martial GT, Dalhat MM, Ward S, Tante O, Nguku PM, Hamadi A, Ilori E. Improving cross-border preparedness and response: lessons learned from 3 Lassa fever outbreaks across Benin, Nigeria, and Togo, 2017\u20132019. Health security. 2020;18[S1]:S-105.","DOI":"10.1089\/hs.2019.0080"},{"key":"2585_CR28","doi-asserted-by":"crossref","unstructured":"Patassi AA, Landoh DE, Mebiny-Essoh Tchalla A, Halatoko WA, Assane H, Saka B, Naba MA, Yaya I, Edou KA, Tamekloe TA, Banla AK. Emergence of lassa fever disease in Northern Togo: report of two cases in oti district in 2016. Case Rep Infect Dis. 2017;2017[1]:8242313.","DOI":"10.1155\/2017\/8242313"},{"key":"2585_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","volume":"59","author":"N Sogoba","year":"2012","unstructured":"Sogoba N, Feldmann H, Safronetz D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health. 2012;59:43\u20137.","journal-title":"Zoonoses Public Health"},{"key":"2585_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fmicb.2015.01037","volume":"6","author":"JT Manning","year":"2015","unstructured":"Manning JT, Forrester N, Paessler S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front Microbiol. 2015;6:1037.","journal-title":"Front Microbiol"},{"key":"2585_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2217\/fmb-2019-0237","volume":"152","author":"BE Bache","year":"2020","unstructured":"Bache BE, Grobusch MP, Agnandji ST. Safety, immunogenicity and risk\u2013benefit analysis of rVSV-\u2206G-ZEBOV-GP [V920] Ebola vaccine in phase I\u2013III clinical trials across regions. Future Microbiol. 2020;152:85\u2013106.","journal-title":"Future Microbiol"},{"key":"2585_CR32","doi-asserted-by":"crossref","unstructured":"Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386[9996]:857\u2009\u2013\u200966.","DOI":"10.1016\/S0140-6736(15)61117-5"},{"key":"2585_CR33","doi-asserted-by":"crossref","unstructured":"Piszczatoski CR, Gums JG. Ervebo [Ebola Zaire vaccine, live\/rVSV\u2206G-ZEBOV-GP]: the first licensed vaccine for the prevention of Ebola virus disease. J Pharm Technol. 2020;36(6):243\u201350.","DOI":"10.1177\/8755122520950692"},{"issue":"6","key":"2585_CR34","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Str\u00f6her U, Fernando L, Daddario KM, Guttieri MC. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2(6):e183.","journal-title":"PLoS Med"},{"issue":"4","key":"2585_CR35","doi-asserted-by":"publisher","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis. 2015;9(4):e0003736.","journal-title":"PLoS Negl Trop Dis"},{"key":"2585_CR36","doi-asserted-by":"crossref","unstructured":"Cross RW, Woolsey C, Prasad AN, Borisevich V, Agans KN, Deer DJ, Geisbert JB, Dobias NS, Fenton KA, Geisbert TW. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep. 2022;40[3].","DOI":"10.1016\/j.celrep.2022.111094"},{"key":"2585_CR37","doi-asserted-by":"crossref","unstructured":"Stein DR, Warner BM, Soule G, Tierney K, Frost KL, Booth S, Safronetz D. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. npj Vaccines. 2019;4[1]:8.","DOI":"10.1038\/s41541-019-0104-x"},{"key":"2585_CR38","first-page":"10","volume":"923","author":"D Matassov","year":"2018","unstructured":"Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQ, Burnaugh A, Rudge TL Jr. Single-dose trivalent VesiculoVax vaccine protects macaques from lethal Ebolavirus and Marburgvirus challenge. J Virol. 2018;923:10\u2013128.","journal-title":"J Virol"},{"key":"2585_CR39","doi-asserted-by":"crossref","unstructured":"Cross RW, Xu R, Matassov D, Hamm S, Latham TE, Gerardi CS, Nowak RM, Geisbert JB, Ota-Setlik A, Agans KN, Luckay A. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J Clin Investig. 2020;130[1]:539\u2009\u2013\u200951.","DOI":"10.1172\/JCI131958"},{"issue":"2","key":"2585_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3201\/eid2102.141649","volume":"21","author":"A Marzi","year":"2015","unstructured":"Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis virus\u2013based vaccines against Lassa and Ebola viruses. Emerg Infect Dis. 2015;21(2):305.","journal-title":"Emerg Infect Dis"},{"key":"2585_CR41","doi-asserted-by":"crossref","unstructured":"Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Mu\u00f1oz P, Moon JE, Ruck RC, Bennett JW, Twomey PS. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376[4]:330\u2009\u2013\u200941.","DOI":"10.1056\/NEJMoa1414216"},{"key":"2585_CR42","doi-asserted-by":"crossref","unstructured":"Heppner DG, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA. Safety and immunogenicity of the rVSV\u2206 G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17[8]:854\u2009\u2013\u200966.","DOI":"10.1016\/S1473-3099(17)30313-4"},{"key":"2585_CR43","doi-asserted-by":"crossref","unstructured":"Stein DR, Sroga P, Warner BM, Deschambault Y, Poliquin G, Safronetz D. Evaluating temperature sensitivity of vesicular stomatitis virus\u2013based vaccines. Emerg Infect Dis. 2019;25[8]:1563.","DOI":"10.3201\/eid2508.190281"},{"key":"2585_CR44","unstructured":"Gupta S, IAVI VSV Lassa Fever Vaccine Candidate Development Overview. 2022 Oct. Accessed Aug 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/day1_session2_4_swati-gupta_lassa-vaccine-meeting_nigeria.pdf?sfvrsn=a64f5402_3"},{"key":"2585_CR45","unstructured":"Malkin E, Baden L, Kieh M, Fitz-Patrick D, Diemert D, Mutua G, Philiponis V, Zaric M, Hunt D, Barin B, Engelbrecht M, Malherbe M, Walker K, Lehrman J, Fast P, Parks C, Gupta SB. Aug. First Safety & Immunogenicity Data from a FIH, Placebo-controlled, Dose-escalation Trial of a Recombinant Vesicular Stomatitis Virus-based Lassa Fever Vaccine in Healthy Adults. From IAVI. Accessed 2024. https:\/\/www.iavi.org\/wp-content\/uploads\/2023\/11\/C102_ASTMH_Poster_Chicago2023.pdf"},{"key":"2585_CR46","doi-asserted-by":"crossref","unstructured":"Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol. 2005;79[22]:13934\u201342.","DOI":"10.1128\/JVI.79.22.13934-13942.2005"},{"key":"2585_CR47","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14760584.2016.1184575","volume":"159","author":"IS Lukashevich","year":"2016","unstructured":"Lukashevich IS, Pushko P. Vaccine platforms to control Lassa fever. Expert Rev Vaccines. 2016;159:1135\u201350.","journal-title":"Expert Rev Vaccines"},{"key":"2585_CR48","doi-asserted-by":"crossref","unstructured":"Carrion R Jr, Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, Salvato MS. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine. 2007;25[20]:4093\u2009\u2013\u2009102.","DOI":"10.1016\/j.vaccine.2007.02.038"},{"key":"2585_CR49","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","volume":"2641","author":"IS Lukashevich","year":"2008","unstructured":"Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, Bryant J. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008;2641:5246\u201354.","journal-title":"Vaccine"},{"key":"2585_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-10-52","volume":"10","author":"JC Zapata","year":"2013","unstructured":"Zapata JC, Poonia B, Bryant J, Davis H, Ateh E, George L, Crasta O, Zhang Y, Slezak T, Jaing C, Pauza CD. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J. 2013;10:1\u20131.","journal-title":"Virol J"},{"key":"2585_CR51","unstructured":"L\u00e9zard L. INOVIO completes enrollment of phase 1B clinical trial for its DNA vaccine candidate against Lassa Fever, INO-4500, in West Africa. 2021."},{"key":"2585_CR52","doi-asserted-by":"crossref","unstructured":"Cashman KA, Broderick KE, Wilkinson ER, Shaia CI, Bell TM, Shurtleff AC, Spik KW, Badger CV, Guttieri MC, Sardesai NY, Schmaljohn CS. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation. Vaccines. 2013;1[3]:262\u2009\u2013\u200977.","DOI":"10.3390\/vaccines1030262"},{"key":"2585_CR53","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"1312","author":"KA Cashman","year":"2017","unstructured":"Cashman KA, Wilkinson ER, Shaia CI, Facemire PR, Bell TM, Bearss JJ, Shamblin JD, Wollen SE, Broderick KE, Sardesai NY, Schmaljohn CS. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum Vaccines Immunotherapeutics. 2017;1312:2902\u201311.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"2585_CR54","doi-asserted-by":"crossref","unstructured":"Jiang J, Banglore P, Cashman KA, Schmaljohn CS, Schultheis K, Pugh H, Nguyen J, Humeau LM, Broderick KE, Ramos SJ. Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques. Volume 19. Human Vaccines & Immunotherapeutics; 2019 Jun.","DOI":"10.1080\/21645515.2019.1616499"},{"key":"2585_CR55","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","volume":"39210165","author":"EC Reisinger","year":"2018","unstructured":"Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M, Tauber E, Ramsauer K. Immunogenicity, safety, and tolerability of the measles-vectored Chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet. 2018;39210165:2718\u201327.","journal-title":"Lancet"},{"key":"2585_CR56","doi-asserted-by":"crossref","unstructured":"Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med. 2019;11[512]:eaaw3163.","DOI":"10.1126\/scitranslmed.aaw3163"},{"key":"2585_CR57","doi-asserted-by":"crossref","unstructured":"Mateo M, Reynard S, Journeaux A, Germain C, Hortion J, Carnec X, Picard C, Baillet N, Borges-Cardoso V, Merabet O, Vallve A. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci Transl Med. 2021;13[597]:eabf6348.","DOI":"10.1126\/scitranslmed.abf6348"},{"key":"2585_CR58","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(23)00048-X","volume":"40110384","author":"R Tschismarov","year":"2023","unstructured":"Tschismarov R, Van Damme P, Germain C, De Coster I, Mateo M, Reynard S, Journeaux A, Tomberger Y, Withanage K, Haslwanter D, Terler K. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. Lancet. 2023;40110384:1267\u201376.","journal-title":"Lancet"},{"key":"2585_CR59","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","volume":"3308552","author":"JC Clegg","year":"1987","unstructured":"Clegg JC, Lloyd G. Vaccinia recombinant expressing lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet. 1987;3308552:186\u20138.","journal-title":"Lancet"},{"key":"2585_CR60","doi-asserted-by":"crossref","unstructured":"Morrison HG, Bauer SP, Lange JV, Esposito JI, McCormick JB, Auperin DD. Protection of guinea pigs from Lassa fever by Vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology. 1989;171[1]:179\u2009\u2013\u200988.","DOI":"10.1016\/0042-6822(89)90525-4"},{"key":"2585_CR61","doi-asserted-by":"crossref","unstructured":"Fisher-Hoch SP, McCormick JB, Auperin D, Brown BG, Castor M, Perez G, Ruo S, Conaty A, Brammer L, Bauer S. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proceedings of the National Academy of Sciences. 1989;86[1]:317\u2009\u2013\u200921.","DOI":"10.1073\/pnas.86.1.317"},{"key":"2585_CR62","doi-asserted-by":"crossref","unstructured":"Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for Lassa fever. J Virol. 2000;74[15]:6777\u201383.","DOI":"10.1128\/JVI.74.15.6777-6783.2000"},{"key":"2585_CR63","doi-asserted-by":"crossref","unstructured":"Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28[3]:632\u2009\u2013\u200949.","DOI":"10.1016\/j.vaccine.2009.09.098"},{"key":"2585_CR64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","volume":"3452","author":"PJ Bredenbeek","year":"2006","unstructured":"Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, Carrion R. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology. 2006;3452:299\u2013304.","journal-title":"Virology"},{"key":"2585_CR65","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","volume":"296","author":"X Jiang","year":"2011","unstructured":"Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011;296:1248\u201357.","journal-title":"Vaccine"},{"key":"2585_CR66","doi-asserted-by":"crossref","unstructured":"Kirsebom FC, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal J. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. Nat Commun. 2022;13[1]:7688.","DOI":"10.1038\/s41467-022-35168-7"},{"key":"2585_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2019.03.008","volume":"215","author":"J Purushotham","year":"2019","unstructured":"Purushotham J, Lambe T, Gilbert SC. Vaccine platforms for the prevention of Lassa fever. Immunol Lett. 2019;215:1\u20131.","journal-title":"Immunol Lett"},{"key":"2585_CR68","doi-asserted-by":"crossref","unstructured":"Mendoza EJ, Warner B, Kobinger G, Ogden NH, Safronetz D. Baited vaccines: a strategy to mitigate rodent-borne viral zoonoses in humans. Zoonoses Public Health. 2018;65[6]:711\u2009\u2013\u200927.","DOI":"10.1111\/zph.12487"},{"key":"2585_CR69","doi-asserted-by":"crossref","unstructured":"Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE. 2012;7[7]:e40385.","DOI":"10.1371\/journal.pone.0040385"},{"key":"2585_CR70","doi-asserted-by":"crossref","unstructured":"Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014;22[3]:668\u2009\u2013\u200974.","DOI":"10.1038\/mt.2013.284"},{"key":"2585_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","volume":"29","author":"L Coughlan","year":"2018","unstructured":"Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, Lawrie AM. Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine. 2018;29:146\u201354.","journal-title":"EBioMedicine"},{"key":"2585_CR72","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/mt.2016.83","volume":"248","author":"MO Afolabi","year":"2016","unstructured":"Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, N\u00e9bi\u00e9 I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ. Safety and immunogenicity of ChAd63 and MVA ME-TRAP in west African children and infants. Mol Ther. 2016;248:1470\u20137.","journal-title":"Mol Ther"},{"key":"2585_CR73","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.vaccine.2016.03.061","volume":"3420","author":"P Dulal","year":"2016","unstructured":"Dulal P, Wright D, Ashfield R, Hill AV, Charleston B, Warimwe GM. Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Vaccine. 2016;3420:2296\u20138.","journal-title":"Vaccine"},{"key":"2585_CR74","doi-asserted-by":"crossref","unstructured":"Fischer RJ, Purushotham JN, van Doremalen N, Sebastian S, Meade-White K, Cordova K, Letko M, Jeremiah Matson M, Feldmann F, Haddock E, LaCasse R. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. npj Vaccines. 2021;6[1]:32.","DOI":"10.1038\/s41541-021-00291-x"},{"key":"2585_CR75","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.amsu.2021.102988","volume":"73","author":"SH Ahmed","year":"2022","unstructured":"Ahmed SH, Shaikh TG, Waseem S, Qadir NA, Yousaf Z, Ullah I. Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: a narrative review. Annals Med Surg. 2022;73:102988.","journal-title":"Annals Med Surg"},{"key":"2585_CR76","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1016\/j.vaccine.2008.05.046","volume":"2633","author":"JM Thompson","year":"2008","unstructured":"Thompson JM, Whitmore AC, Staats HF, Johnston RE. Alphavirus replicon particles acting as adjuvants promote CD8\u2009+\u2009T cell responses to co-delivered antigen. Vaccine. 2008;2633:4267\u201375.","journal-title":"Vaccine"},{"key":"2585_CR77","doi-asserted-by":"crossref","unstructured":"Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol. 2001;75[23]:11677\u201385.","DOI":"10.1128\/JVI.75.23.11677-11685.2001"},{"key":"2585_CR78","doi-asserted-by":"crossref","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403[10432]:1192\u2009\u2013\u2009204.","DOI":"10.1016\/S0140-6736(23)02444-3"},{"key":"2585_CR79","doi-asserted-by":"crossref","unstructured":"Ronk AJ, Lloyd NM, Zhang M, Atyeo C, Perrett HR, Mire CE, Hastie KM, Sanders RW, Brouwer PJ, Saphire EO, Ward AB. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat Commun. 2023;14[1]:5603.","DOI":"10.1038\/s41467-023-41376-6"},{"key":"2585_CR80","first-page":"e00578","volume":"986","author":"M Hashizume","year":"2024","unstructured":"Hashizume M, Takashima A, Iwasaki M. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice. J Virol. 2024;986:e00578\u201324.","journal-title":"J Virol"},{"key":"2585_CR81","first-page":"10","volume":"111","author":"Y Cai","year":"2020","unstructured":"Cai Y, Ye C, Cheng B, Nogales A, Iwasaki M, Yu S, Cooper K, Liu DX, Hart R, Adams R, Brady T. A Lassa fever live-attenuated vaccine based on codon deoptimization of the viral glycoprotein gene. Mbio. 2020;111:10\u2013128.","journal-title":"Mbio"},{"key":"2585_CR82","first-page":"10","volume":"112","author":"Y Cai","year":"2020","unstructured":"Cai Y, Iwasaki M, Motooka D, Liu DX, Yu S, Cooper K, Hart R, Adams R, Burdette T, Postnikova EN, Kurtz J. A Lassa virus live-attenuated vaccine candidate based on rearrangement of the intergenic region. Mbio. 2020;112:10\u2013128.","journal-title":"Mbio"},{"key":"2585_CR83","doi-asserted-by":"crossref","unstructured":"Brouwer PJ, Antanasijevic A, Ronk AJ, M\u00fcller-Kr\u00e4uter H, Watanabe Y, Claireaux M, Perrett HR, Bijl TP, Grobben M, Umotoy JC, Schriek AI. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Cell Host Microbe. 2022;30[12]:1759\u201372.","DOI":"10.1016\/j.chom.2022.10.018"},{"key":"2585_CR84","doi-asserted-by":"crossref","unstructured":"M\u00fcller H, Fehling SK, Dorna J, Urbanowicz RA, Oestereich L, Krebs Y, Kolesnikova L, Schauflinger M, Kr\u00e4hling V, Magassouba NF, Fichet-Calvet E. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. npj Vaccines. 2020;5[1]:71.","DOI":"10.1038\/s41541-020-00219-x"},{"key":"2585_CR85","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/infdis\/jiab014","volume":"2246","author":"D Kurup","year":"2021","unstructured":"Kurup D, Fisher CR, Scher G, Yankowski C, Testa A, Keshwara R, Abreu-Mota T, Lambert R, Ferguson M, Rinaldi W, Ruiz L. Tetravalent rabies-vectored Filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates. J Infect Dis. 2021;2246:995\u20131004.","journal-title":"J Infect Dis"},{"key":"2585_CR86","doi-asserted-by":"crossref","unstructured":"Scher G, Yankowski C, Kurup D, Josleyn NM, Wilkinson ER, Wells J, Steffens J, Lynn G, Vantongeren S, Zeng X, Twenhafel N. Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. npj Vaccines. 2024;9[1]:143.","DOI":"10.1038\/s41541-024-00930-z"},{"key":"2585_CR87","doi-asserted-by":"crossref","unstructured":"Sullivan BM, Sakabe S, Hartnett JN, Ngo N, Goba A, Momoh M, Demby Sandi J, Kanneh L, Cubitt B, Garcia SD, Ware BC. High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathog. 2020;16[3]:e1008352.","DOI":"10.1371\/journal.ppat.1008352"},{"key":"2585_CR88","doi-asserted-by":"crossref","unstructured":"Hartnett JN, Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS, Muncy IJ, Goba A, Momoh M, Fullah M, Mire CE. Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virol. 2015;10[5]:559\u2009\u2013\u200984.","DOI":"10.2217\/fvl.15.41"},{"key":"2585_CR89","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.coviro.2019.06.010","volume":"37","author":"BM Warner","year":"2019","unstructured":"Warner BM, Siragam V, Stein DR. Assessment of antiviral therapeutics in animal models of Lassa fever. Curr Opin Virol. 2019;37:84\u201390.","journal-title":"Curr Opin Virol"},{"key":"2585_CR90","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","volume":"3378749","author":"O Reichard","year":"1991","unstructured":"Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 1991;3378749:1058\u201361.","journal-title":"Lancet"},{"key":"2585_CR91","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJM198306163082403","volume":"30824","author":"CB Hall","year":"1983","unstructured":"Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ. Aerosolized Ribavirin treatment of infants with respiratory syncytial viral infection: a randomized double-blind study. N Engl J Med. 1983;30824:1443\u20137.","journal-title":"N Engl J Med"},{"key":"2585_CR92","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00705-011-1222-6","volume":"157","author":"G Zhang","year":"2012","unstructured":"Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, Hu W. In vitro and in vivo evaluation of Ribavirin and Pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669\u201379.","journal-title":"Arch Virol"},{"key":"2585_CR93","doi-asserted-by":"crossref","unstructured":"Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, Levy H, Koster FT, Baum K, Lindemulder A, Wang W. Placebo-controlled, double-blind trial of intravenous Ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39[9]:1307\u201313.","DOI":"10.1086\/425007"},{"key":"2585_CR94","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","volume":"7910","author":"C Hultgren","year":"1998","unstructured":"Hultgren C, Milich DR, Weiland O, S\u00e4llberg M. The antiviral compound Ribavirin modulates the T helper [Th] 1\/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;7910:2381\u201391.","journal-title":"J Gen Virol"},{"key":"2585_CR95","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","volume":"1415","author":"PB Jahrling","year":"1980","unstructured":"Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with Ribavirin. J Infect Dis. 1980;1415:580\u20139.","journal-title":"J Infect Dis"},{"key":"2585_CR96","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","volume":"1493","author":"PB Jahrling","year":"1984","unstructured":"Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with Ribavirin in cynomolgus monkeys. J Infect Dis. 1984;1493:420\u20137.","journal-title":"J Infect Dis"},{"key":"2585_CR97","doi-asserted-by":"crossref","unstructured":"Oestereich L, Rieger T, L\u00fcdtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Mu\u00f1oz-Fontela C, G\u00fcnther S. Efficacy of favipiravir alone and in combination with Ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis. 2016;213[6]:934\u20138.","DOI":"10.1093\/infdis\/jiv522"},{"key":"2585_CR98","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Rosenke, K., Westover, J. B., Martellaro, C., Okumura, A., Furuta,Y., \u2026 Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Scientific reports. 2015;5[1]:14775.","DOI":"10.1038\/srep14775"},{"key":"2585_CR99","doi-asserted-by":"crossref","unstructured":"Jahrling PB, Smith SH, Hesse RA, Rhoderick JB. Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun. 1982;37[2]:771\u20138.","DOI":"10.1128\/iai.37.2.771-778.1982"},{"key":"2585_CR100","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1086\/657315","volume":"5112","author":"DG Bausch","year":"2010","unstructured":"Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral Ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010;5112:1435\u201341.","journal-title":"Clin Infect Dis"},{"key":"2585_CR101","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/cid\/cix406","volume":"655","author":"VN Raabe","year":"2017","unstructured":"Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, Lyon GM, Vanairsdale S, Faber K, Becker S, Eickmann M. Favipiravir and Ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis. 2017;655:855\u20139.","journal-title":"Clin Infect Dis"},{"key":"2585_CR102","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","volume":"113","author":"P Koszalka","year":"2017","unstructured":"Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;113:240\u20136.","journal-title":"Influenza Other Respir Viruses"},{"key":"2585_CR103","doi-asserted-by":"crossref","unstructured":"Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro C, Feldmann F, Saturday G, Lovaglio J, Scott DP, Furuta Y, Komeno T. Use of favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis. 2018;24[9]:1696.","DOI":"10.3201\/eid2409.180233"},{"key":"2585_CR104","first-page":"1448","volume":"37515","author":"II Prevail","year":"2016","unstructured":"Prevail II, Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;37515:1448\u201356.","journal-title":"N Engl J Med"},{"key":"2585_CR105","doi-asserted-by":"publisher","first-page":"721328","DOI":"10.3389\/fimmu.2021.721328","volume":"12","author":"O Tshiani Mbaya","year":"2021","unstructured":"Tshiani Mbaya O, Mukumbayi P, Mulangu S. Insights on current FDA-approved monoclonal antibodies against Ebola virus infection. Front Immunol. 2021;12:721328.","journal-title":"Front Immunol"},{"key":"2585_CR106","doi-asserted-by":"crossref","unstructured":"Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discovery. 2022;21[9]:676\u2009\u2013\u200996.","DOI":"10.1038\/s41573-022-00495-3"},{"key":"2585_CR107","doi-asserted-by":"crossref","unstructured":"Warner BM, Safronetz D, Stein DR. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug design, development and therapy. 2018 Aug 14:2519\u201327.","DOI":"10.2147\/DDDT.S147276"},{"key":"2585_CR108","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jmv.1890120203","volume":"122","author":"PB Jahrling","year":"1983","unstructured":"Jahrling PB. Protection of Lassa virus-infected guinea pigs with Lassa\u2010immune plasma of guinea pig, primate, and human origin. J Med Virol. 1983;122:93\u2013102.","journal-title":"J Med Virol"},{"key":"2585_CR109","doi-asserted-by":"crossref","unstructured":"Frame JD, Verbrugge GP, Gill RG, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg. 1984;78[3]:319\u2009\u2013\u200924.","DOI":"10.1016\/0035-9203(84)90107-X"},{"key":"2585_CR110","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","volume":"793","author":"PB Jahrling","year":"1985","unstructured":"Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg. 1985;793:380\u20134.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2585_CR111","doi-asserted-by":"crossref","unstructured":"Oestereich L, M\u00fcller-Kr\u00e4uter H, Pallasch E, Strecker T. Passive transfer of animal-derived polyclonal hyperimmune antibodies provides Protection of mice from Lethal Lassa Virus infection. Viruses. 2023;15[7]:1436.","DOI":"10.3390\/v15071436"},{"key":"2585_CR112","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, Khan SH. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res. 2016;133:218\u201322.","journal-title":"Antiviral Res"},{"key":"2585_CR113","doi-asserted-by":"crossref","unstructured":"Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med. 2017;23[10]:1146\u20139.","DOI":"10.1038\/nm.4396"},{"key":"2585_CR114","doi-asserted-by":"crossref","unstructured":"Cross RW, Heinrich ML, Fenton KA, Borisevich V, Agans KN, Prasad AN, Woolsey C, Deer DJ, Dobias NS, Rowland MM, Lathigra R. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proceedings of the National Academy of Sciences. 2023;120[34]:e2304876120.","DOI":"10.1073\/pnas.2304876120"},{"key":"2585_CR115","doi-asserted-by":"crossref","unstructured":"Woolsey C, Cross RW, Prasad AN, Agans KN, Borisevich V, Deer DJ, Dobias NS, Fears AC, Harrison MB, Heinrich ML, Fenton KA. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates. Emerg Microbes Infections. 2024;13[1]:2301061.","DOI":"10.1080\/22221751.2023.2301061"},{"key":"2585_CR116","doi-asserted-by":"crossref","unstructured":"Li H, Buck T, Zandonatti M, Yin J, Moon-Walker A, Fang J, Koval A, Heinrich ML, Rowland MM, Diaz Avalos R, Schendel SL. A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus. Sci Transl Med. 2022;14[668]:eabq0991.","DOI":"10.1126\/scitranslmed.abq0991"},{"key":"2585_CR117","doi-asserted-by":"crossref","unstructured":"Cross RW, Fenton KA, Woolsey C, Prasad AN, Borisevich V, Agans KN, Deer DJ, Dobias NS, Fears AC, Heinrich ML, Geisbert JB. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. Cell Rep Med. 2024;5[2].","DOI":"10.1016\/j.xcrm.2024.101392"},{"key":"2585_CR118","doi-asserted-by":"crossref","unstructured":"M\u00fcller S, G\u00fcnther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother. 2007;51[6]:2215\u20138.","DOI":"10.1128\/AAC.01368-06"},{"key":"2585_CR119","doi-asserted-by":"crossref","unstructured":"Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, Amberg SM. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008;82[21]:10768\u201375.","DOI":"10.1128\/JVI.00941-08"},{"key":"2585_CR120","doi-asserted-by":"crossref","unstructured":"Cashman KA, Smith MA, Twenhafel NA, Larson RA, Jones KF, Allen RD III, Dai D, Chinsangaram J, Tove \u2019CB, Hruby DE, Amberg SM. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011;90[1]:70\u2009\u2013\u20099.","DOI":"10.1016\/j.antiviral.2011.02.012"},{"key":"2585_CR121","doi-asserted-by":"crossref","unstructured":"Madu IG, Files M, Gharaibeh DN, Moore AL, Jung KH, Gowen BB, Dai D, Jones KF, Tyavanagimatt SR, Burgeson JR, Korth MJ. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018;14[12]:e1007439.","DOI":"10.1371\/journal.ppat.1007439"},{"key":"2585_CR122","first-page":"10","volume":"938","author":"CE Hulseberg","year":"2019","unstructured":"Hulseberg CE, F\u00e9n\u00e9ant L, Szyma\u0144ska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol. 2019;938:10\u2013128.","journal-title":"J Virol"},{"key":"2585_CR123","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.antiviral.2017.11.004","volume":"149","author":"X Tong","year":"2018","unstructured":"Tong X, Smith J, Bukreyeva N, Koma T, Manning JT, Kalkeri R, Kwong AD, Paessler S. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antiviral Res. 2018;149:34\u201340.","journal-title":"Antiviral Res"},{"key":"2585_CR124","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.antiviral.2019.03.014","volume":"167","author":"X Zhang","year":"2019","unstructured":"Zhang X, Yan F, Tang K, Chen Q, Guo J, Zhu W, He S, Banadyga L, Qiu X, Guo Y. Identification of a clinical compound losmapimod that blocks Lassa virus entry. Antiviral Res. 2019;167:68\u201377.","journal-title":"Antiviral Res"},{"key":"2585_CR125","doi-asserted-by":"publisher","first-page":"1206872","DOI":"10.3389\/fmicb.2023.1206872","volume":"14","author":"S Akash","year":"2023","unstructured":"Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR, Gupta G, Rajakumari V, Chinni SV, Ramachawolran G, Saleh FM. Development of a new drug candidate for the inhibition of Lassa virus glycoprotein and nucleoprotein by modification of evodiamine as promising therapeutic agents. Front Microbiol. 2023;14:1206872.","journal-title":"Front Microbiol"},{"key":"2585_CR126","doi-asserted-by":"publisher","first-page":"104701","DOI":"10.1016\/j.antiviral.2019.104701","volume":"174","author":"X Zhang","year":"2020","unstructured":"Zhang X, Tang K, Guo Y. The antifungal isavuconazole inhibits the entry of Lassa virus by targeting the stable signal peptide-GP2 subunit interface of Lassa virus glycoprotein. Antiviral Res. 2020;174:104701.","journal-title":"Antiviral Res"},{"key":"2585_CR127","first-page":"10","volume":"958","author":"Y Liu","year":"2021","unstructured":"Liu Y, Guo J, Cao J, Zhang G, Jia X, Wang P, Xiao G, Wang W. Screening of botanical drugs against Lassa virus entry. J Virol. 2021;958:10\u2013128.","journal-title":"J Virol"},{"key":"2585_CR128","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.antiviral.2018.10.011","volume":"160","author":"K Tang","year":"2018","unstructured":"Tang K, He S, Zhang X, Guo J, Chen Q, Yan F, Banadyga L, Zhu W, Qiu X, Guo Y. Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever. Antiviral Res. 2018;160:87\u201393.","journal-title":"Antiviral Res"},{"key":"2585_CR129","doi-asserted-by":"crossref","unstructured":"Wang MK, Ren T, Liu H, Lim SY, Lee K, Honko A, Zhou H, Dyall J, Hensley L, Gartin AK, Cunningham JM. Critical role for cholesterol in lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1. PLoS Pathog. 2018;14[9]:e1007322.","DOI":"10.1371\/journal.ppat.1007322"},{"key":"2585_CR130","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1128\/JVI.02019-10","volume":"852","author":"S Urata","year":"2011","unstructured":"Urata S, Yun N, Pasquato A, Paessler S, Kunz S, De La Torre JC. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol. 2011;852:795\u2013803.","journal-title":"J Virol"},{"key":"2585_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-4-1","volume":"4","author":"FM Uckun","year":"2004","unstructured":"Uckun FM, Petkevich AS, Vassilev AO, Tibbles HE, Titov L. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004;4:1\u20137.","journal-title":"BMC Infect Dis"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02585-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:04:34Z","timestamp":1734588274000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02585-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2585"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02585-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}